Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Oncothyreon Inc. Stories

2010-08-31 07:00:00

SEATTLE, Aug. 31 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the appointment of Julie M. Eastland as Chief Financial Officer and Vice President, Corporate Development, effective September 7, 2010. Ms. Eastland's responsibilities will include financial management, investor relations and business development. "Ms. Eastland brings more than 25 years of financial management experience to Oncothyreon," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "We...

2010-08-05 15:01:00

SEATTLE, Aug. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported a net loss of $4.3 million or $0.17 per basic and diluted share for the quarter ended June 30, 2010, compared with a net loss of $6.3 million or $0.30 per basic and diluted share for the comparable period in 2009. Oncothyreon also reported a net loss of $5.1 million or $0.20 per basic and diluted share for the six months ended June 30, 2010, compared with a net loss of $8.8 million or $0.43 per basic and...

2010-07-26 07:00:00

SEATTLE, WA, July 26 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) will conduct a conference call to discuss its second quarter 2010 financial results on Thursday, August 5, 2010 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon's...

2010-07-07 07:00:00

SEATTLE, WA, July 7 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it has secured a committed equity financing facility under which it may sell up to $20 million of its shares of common stock to Small Cap Biotech Value, Ltd. (the "investor") over a 24-month period. Oncothyreon is not obligated to use the facility and remains free to enter into and consummate other equity and debt financing transactions. Oncothyreon intends to use the proceeds from future sales...

2010-06-07 08:00:00

DESCRIBES PHASE 2 DEVELOPMENT PLANS FOR PX-866 SEATTLE, WA, June 7 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") announced that results from Phase 1 clinical trials of the Company's small molecule product candidates PX-866, an irreversible inhibitor of PI-3 kinase, and PX-478, an inhibitor of HIF-1 alpha, were presented today at the American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, IL. In conjunction with the presentations, the Company...

2010-06-03 07:00:00

SEATTLE, WA, June 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June. Presentations include: - The Noble Financial Sixth Annual Equity Conference on Tuesday, June 8, 2010 at 10:30 a.m. Eastern Time in Hollywood, FL. - The 9th Annual Needham Healthcare Conference on Thursday, June 10, 2010 at 11:20 a.m. Eastern Time...

2010-05-12 07:00:00

SEATTLE, May 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference taking place in London on May 16-18, 2010. Dr. Kirkman will present at 10:15 a.m. British Summer Time (5:15 a.m. Eastern Daylight Time) on Tuesday, May 18 at the Grosvenor House Hotel. A live and archived webcast of the presentation will be accessible by visiting...

2010-05-06 15:04:00

SEATTLE, WA, May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported a net loss of $0.8 million or $0.03 per basic and diluted share for the quarter ended March 31, 2010, compared with a net loss of $2.5 million or $0.13 per basic and diluted share for the comparable period in 2009. The decrease in net loss is primarily the result of a decrease in fair value of warrant liability of $4.6 million, offset by an increase in net loss from operations. Net loss...

2010-05-06 15:02:00

Concludes restatement of prior financial results Company to hold conference call at 4:30 EDT today SEATTLE, May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported financial results for the year and quarter ending December 31, 2009. The Company also announced today that it filed its Annual Report on Form 10-K for the year ended December 31, 2009 (the "2009 Form 10-K"), which concludes the restatement of its historical financial results. 2009 Financial...

2010-05-05 15:05:00

SEATTLE, May 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today it will report its 2009 year end and first quarter 2010 financial results on Thursday, May 6, 2010 after the close of U.S. financial markets, followed by a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on...